Biggest News Aggregation in the World
📰 Circulatory Support Program News

Circulatory Support Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Circulatory Support Program. Real-time updates on events, politics, business and more.

InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01

InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01 - read this article along with other careers information, tips and advice on BioSpace
Stanford University United States United Kingdom British Columbia Thomas Smeenk Barry Morgan

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Hemostemix Inc.: Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation

Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment
Stanford University United States Thomas Smeenk Renzo Cecere Nadia Giannetti Julie Quenneville

Hemostemix Inc.: Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials

Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead
Thomas Smeenk Heart Transplantation Program Myocardial Regeneration Laboratory Regulation Service Provider Principal Investigator Of The Research Institute Circulatory Support Program

Hemostemix Inc.: Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board

Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC
Thomas Smeenk Renzo Cecere Heart Transplantation Program Myocardial Regeneration Laboratory Regulation Service Provider Principal Investigator Of The Research Institute

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science